论文部分内容阅读
对５２例蛛网膜下腔出血（ＳＡＨ）患者随机分为硫酸镁治疗组（２８例）和常规治疗对照组（２４例），以观察硫酸镁防治迟发性脑血管痉挛（ＤＣＶＳ）的疗效。发现硫酸镁组有５例发生ＤＣＶＳ，对照组有１１例（Ｐ＜０．０５）；因ＤＣＶＳ而出现延迟性脑缺血性神经功能障碍（ＤＩＮＤ）者经头颅ＣＴ证实，硫酸镁组脑梗塞有２例，对照组有６例，两组相比Ｐ＜０．０１；硫酸镁组的死亡率也较对照组低。认为硫酸镁有防治ＳＡＨ后ＤＣＶＳ的作用例再次ＳＡＨ，均死于脑疝。两组相比，硫酸镁组较对照组显著为低，Ｐ＜０．０５。４、在用药过程中未发现明显不良反应，个别患者血压下降，经调慢滴速后血压则回升。用于合并高血压患者，对于控制高血压有一定作用。无中途停药者。附表两组防治ＤＣＶＳ的疗效比较（例数，％）ＤＣＶＳ脑梗塞死亡硫酸镁组（ｎ＝２８）５（１７．９）＊２（７．１）＊＊１（３．６）对照组（ｎ＝２４）１１（４５．８）６（２５）３（１２．５）注：与对照组比较＊Ｐ＜０．０５，＊＊Ｐ＜０．０１讨论ＳＡＨ后ＤＣＶＳ之发生率为１０～６０％［２］。文献报道［３］常用的钙离子拮抗剂尼莫地平大剂量静脉注射或口服均不能扩张痉挛的脑动脉，也不能增加脑血流量，但能降低ＳＡ
Fifty-two patients with subarachnoid hemorrhage (SAH) were randomly divided into magnesium sulfate treatment group (28 cases) and conventional treatment control group (24 cases) to observe the effect of magnesium sulfate in preventing and treating delayed cerebral vasospasm (DCVS). DCVS was found in 5 cases in the group of magnesium sulfate and in 11 cases in the control group (P <0.05). Decreased cerebral ischemic neurological dysfunction (DIND) due to DCVS was confirmed by skull CT and cerebral infarction in magnesium sulfate group There were 2 cases in the control group and 6 cases in the control group, P <0.01 compared with the two groups; the mortality in the magnesium sulfate group was also lower than that in the control group. It is considered that magnesium sulfate has the effect of preventing and treating DCVS after SAH. Once again SAH is died of cerebral hernia. Compared with the two groups, magnesium sulfate group was significantly lower than the control group, P <0.05.4, no significant adverse reactions in the course of medication, individual patients decreased blood pressure, blood pressure dropped after the slow drip is picked up. For patients with hypertension, for the control of hypertension have a role. No stop drug. Table 2 Comparison of efficacy of DCVS in preventing and treating DCVS (n = 28) 5 (17.9) * 2 (7.1) ** 1 (3.6) Control group (N = 24) 11 (45.8) 6 (25) 3 (12.5) Note: Compared with the control group * P <0.05, ** P <0.01 Discussion The incidence of DCVS after SAH was 10 ~ 60% [2]. Reported in the literature [3] commonly used calcium antagonist nimodipine high-dose intravenous or oral can not dilate spasm of cerebral artery, can not increase cerebral blood flow, but can reduce SA